[go: up one dir, main page]

CO6940432A2 - Compuestos de 1-arilcarbonilo-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas - Google Patents

Compuestos de 1-arilcarbonilo-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas

Info

Publication number
CO6940432A2
CO6940432A2 CO14094354A CO14094354A CO6940432A2 CO 6940432 A2 CO6940432 A2 CO 6940432A2 CO 14094354 A CO14094354 A CO 14094354A CO 14094354 A CO14094354 A CO 14094354A CO 6940432 A2 CO6940432 A2 CO 6940432A2
Authority
CO
Colombia
Prior art keywords
arylcarbonyl
oxy
compounds
treatment
neurodegenerative diseases
Prior art date
Application number
CO14094354A
Other languages
English (en)
Inventor
Tatsuki Koike
Masato Yoshikawa
Haruhi Ando
William Farnaby
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47143241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6940432(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6940432A2 publication Critical patent/CO6940432A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
CO14094354A 2011-10-07 2014-05-02 Compuestos de 1-arilcarbonilo-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas CO6940432A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011222741 2011-10-07

Publications (1)

Publication Number Publication Date
CO6940432A2 true CO6940432A2 (es) 2014-05-09

Family

ID=47143241

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14094354A CO6940432A2 (es) 2011-10-07 2014-05-02 Compuestos de 1-arilcarbonilo-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas

Country Status (43)

Country Link
US (11) US8648079B2 (es)
EP (1) EP2763979B1 (es)
JP (1) JP6117191B2 (es)
KR (1) KR101967497B1 (es)
CN (1) CN103842356B (es)
AP (1) AP2014007606A0 (es)
AR (1) AR088226A1 (es)
AU (1) AU2012321815B2 (es)
BR (2) BR112014007257B1 (es)
CA (1) CA2851087C (es)
CL (1) CL2014000806A1 (es)
CO (1) CO6940432A2 (es)
CR (1) CR20140151A (es)
CY (1) CY1121549T1 (es)
DK (1) DK2763979T3 (es)
DO (1) DOP2014000064A (es)
EA (1) EA025662B1 (es)
EC (1) ECSP14013329A (es)
ES (1) ES2716531T3 (es)
GE (1) GEP201706608B (es)
HR (1) HRP20190491T1 (es)
HU (1) HUE043171T2 (es)
IL (1) IL231678A (es)
LT (1) LT2763979T (es)
MA (1) MA35623B1 (es)
ME (1) ME03372B (es)
MX (1) MX360706B (es)
MY (1) MY176126A (es)
PE (1) PE20141120A1 (es)
PH (1) PH12014500759A1 (es)
PL (1) PL2763979T3 (es)
PT (1) PT2763979T (es)
RS (1) RS58470B1 (es)
SG (1) SG2014010417A (es)
SI (1) SI2763979T1 (es)
SM (1) SMT201900173T1 (es)
TN (1) TN2014000122A1 (es)
TR (1) TR201902788T4 (es)
TW (1) TWI582084B (es)
UA (1) UA115133C2 (es)
UY (1) UY34365A (es)
WO (1) WO2013054822A1 (es)
ZA (1) ZA201402424B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360706B (es) 2011-10-07 2018-11-14 Takeda Pharmaceuticals Co Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas.
WO2014061676A1 (ja) 2012-10-16 2014-04-24 武田薬品工業株式会社 複素環化合物
CR20150364A (es) 2012-12-11 2016-09-20 Takeda Pharmaceuticals Co Compuesto heterociclico
CN105246486B (zh) 2013-03-13 2020-11-03 萨奇治疗股份有限公司 神经活性甾类化合物
WO2014163162A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
WO2014163161A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
EP3152198B1 (en) * 2014-06-09 2019-02-27 Takeda Pharmaceutical Company Limited Radiolabeled compounds
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス, インコーポレイテッド オキシステロールおよびその使用方法
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
KR20240166589A (ko) 2015-07-06 2024-11-26 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
ES2865258T3 (es) 2015-07-06 2021-10-15 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
JP6807322B2 (ja) * 2015-10-16 2021-01-06 武田薬品工業株式会社 複素環化合物の製造方法
GB201604029D0 (en) * 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
MA44526A (fr) 2016-04-01 2021-06-02 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN109071440A (zh) * 2016-05-13 2018-12-21 日产化学株式会社 2-乙酰基吡啶化合物的制造方法
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
JP7196157B2 (ja) * 2017-08-31 2022-12-26 武田薬品工業株式会社 Cns状態の治療
WO2020027344A1 (en) * 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Ch24h inhibitors for mdd use
EP3852757A1 (en) * 2018-09-20 2021-07-28 Takeda Pharmaceutical Company Limited Ch24h inhibitors for pain use
TW202523658A (zh) * 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
JP2023550654A (ja) * 2020-11-25 2023-12-04 セージ セラピューティクス, インコーポレイテッド 神経変性障害の治療のためのcyp46a1阻害剤としての4-フルオロ-(4-(4-ベンジル)ピペリジン-1-イル)(2-(ピリミジン-4-イル)ピリジン-3-イル)メタノン誘導体および類似化合物
IL309208A (en) 2021-06-11 2024-02-01 Sage Therapeutics Inc Neuroactive steroid for the treatment of alzheimer's disease
AU2022410646A1 (en) * 2021-12-17 2024-05-30 Athira Pharma, Inc. Uses of bicyclic compounds for the treatment of diseases
CN116444477B (zh) * 2023-04-04 2026-01-02 宁波九胜创新医药科技有限公司 一种溴代胡椒环羧酸的制备方法及其用途
WO2025019590A2 (en) * 2023-07-18 2025-01-23 The General Hospital Corporation Proteolysis targeting chimeras for treating neurodegeneration
WO2025126159A1 (en) 2023-12-15 2025-06-19 Takeda Pharmaceutical Company Limited A method for treating a neurological disease in a recreational drug user
WO2025257799A1 (en) 2024-06-14 2025-12-18 Takeda Pharmaceutical Company Limited Methods of treating dravet syndrome

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
ES2245003T3 (es) 1996-08-27 2005-12-16 Praecis Pharmaceuticals Incorporated Moduladores de la agregacion de peptidos beta-amiloides que comprenden d-aminoacidos.
ATE482233T1 (de) 1999-06-28 2010-10-15 Oklahoma Med Res Found Inhibitoren des memapsin 2 und ihre verwendung
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
AU2002248432A1 (en) 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
CA2445568A1 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
AU2003288231A1 (en) 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
DOP2005000039A (es) 2004-03-26 2005-10-31 Aventis Pharma Inc Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
US20060167044A1 (en) 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
WO2006137465A1 (ja) 2005-06-24 2006-12-28 Shionogi & Co., Ltd. 含窒素複素環誘導体
BRPI0619268A2 (pt) * 2005-11-30 2011-09-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
NZ569108A (en) 2005-12-20 2011-09-30 Bristol Myers Squibb Co Formulations of CTLA4Ig stabilised using sugars
AU2007275301A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
WO2008134547A1 (en) 2007-04-25 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using hydroxycyclohexane and hydroxypiperidine compounds in treating sodium channel-mediated diseases or conditions
WO2008153722A1 (en) 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
RS54413B1 (sr) 2008-08-22 2016-04-28 Sanofi [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
JP5316468B2 (ja) 2010-04-09 2013-10-16 株式会社豊田自動織機 リアクトル構造
EA025611B1 (ru) 2010-07-29 2017-01-30 Райджел Фармасьютикалз, Инк. Активирующие ampk гетероциклические соединения и способы их использования
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ1デルタ(ck1デルタ)阻害剤
MX360706B (es) * 2011-10-07 2018-11-14 Takeda Pharmaceuticals Co Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas.

Also Published As

Publication number Publication date
US20170145031A1 (en) 2017-05-25
US20160326136A1 (en) 2016-11-10
TWI582084B (zh) 2017-05-11
SI2763979T1 (sl) 2019-04-30
AU2012321815A1 (en) 2014-04-24
US20140088118A1 (en) 2014-03-27
BR112014007257A2 (pt) 2017-03-28
NZ623185A (en) 2016-01-29
TW201329068A (zh) 2013-07-16
IL231678A0 (en) 2014-05-28
US11174272B2 (en) 2021-11-16
EA025662B1 (ru) 2017-01-30
US20130090341A1 (en) 2013-04-11
KR20140072902A (ko) 2014-06-13
KR101967497B1 (ko) 2019-04-09
AP2014007606A0 (en) 2014-05-31
US9586930B2 (en) 2017-03-07
TR201902788T4 (tr) 2019-03-21
CA2851087C (en) 2019-09-24
PH12014500759A1 (en) 2014-05-12
AU2012321815A8 (en) 2014-06-12
LT2763979T (lt) 2019-03-25
UA115133C2 (uk) 2017-09-25
GEP201706608B (en) 2017-01-25
US20190071455A1 (en) 2019-03-07
US8865717B2 (en) 2014-10-21
EA201490747A1 (ru) 2014-08-29
US20140228373A1 (en) 2014-08-14
CA2851087A1 (en) 2013-04-18
JP2014528904A (ja) 2014-10-30
US10550129B2 (en) 2020-02-04
CN103842356B (zh) 2017-03-15
ME03372B (me) 2020-01-20
US20200157117A1 (en) 2020-05-21
MX360706B (es) 2018-11-14
US20140088146A1 (en) 2014-03-27
US20150376205A1 (en) 2015-12-31
CN103842356A (zh) 2014-06-04
MA35623B1 (fr) 2014-11-01
SG2014010417A (en) 2014-06-27
US9440990B2 (en) 2016-09-13
ES2716531T3 (es) 2019-06-13
US8871766B2 (en) 2014-10-28
IL231678A (en) 2017-03-30
EP2763979B1 (en) 2018-12-26
BR122022001219B1 (pt) 2023-03-14
US20190233436A1 (en) 2019-08-01
AU2012321815B2 (en) 2017-03-09
ECSP14013329A (es) 2014-05-31
UY34365A (es) 2013-05-31
US9193709B2 (en) 2015-11-24
CR20140151A (es) 2014-05-26
JP6117191B2 (ja) 2017-04-19
US20210206781A1 (en) 2021-07-08
AR088226A1 (es) 2014-05-21
US8648079B2 (en) 2014-02-11
SMT201900173T1 (it) 2019-05-10
ZA201402424B (en) 2015-07-29
PT2763979T (pt) 2019-04-12
HRP20190491T1 (hr) 2019-05-03
HUE043171T2 (hu) 2019-08-28
TN2014000122A1 (en) 2015-07-01
PL2763979T3 (pl) 2019-06-28
CL2014000806A1 (es) 2014-09-05
DK2763979T3 (en) 2019-04-01
RS58470B1 (sr) 2019-04-30
MY176126A (en) 2020-07-24
CY1121549T1 (el) 2020-05-29
DOP2014000064A (es) 2014-07-15
BR112014007257B1 (pt) 2023-04-25
US10273245B2 (en) 2019-04-30
PE20141120A1 (es) 2014-09-15
US10144743B2 (en) 2018-12-04
EP2763979A1 (en) 2014-08-13
US10717748B2 (en) 2020-07-21
MX2014004253A (es) 2014-06-11
WO2013054822A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
CO6940432A2 (es) Compuestos de 1-arilcarbonilo-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
CO6821964A2 (es) Compuestos para el tratamiento de la adicción
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
CO6791604A2 (es) Compuesto para liberación controlada de agentes de tratamiento de pozos
CO6801733A2 (es) Silicato de zirconio microporoso para el tratamiento de la hipercalemia
ZA201600317B (en) Bicyclic compounds useful for treating diseases caused by retroviruses
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
DK3305317T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
PT2872497T (pt) Derivados de cromanilo para o tratamento de doenças mitocondriais
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
ZA201501390B (en) Compounds for the treatment of mtor pathway related diseases
BR112013030370A2 (pt) compostos de quinona para tratamento de doenças mediadas por ape1
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
CO6821965A2 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
BR112013033970A2 (pt) compostos e combinações farmacêuticas para o tratamento de doenças cerebrais isquêmicas e neurodegenerativas
IL238592B (en) Compounds for treatment of liver diseases
BR112013030930A2 (pt) composições farmacêuticas combinadas para o tratamento de tumores
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
BR112013020025A2 (pt) derivados de aminoestatina para o tratamento de artrose
DOP2012000106A (es) Procedimiento para el tratamiento de desechos